BofA update shows where active managers are putting money
Xeris Pharmaceuticals Inc. stock reached a 52-week high of $7.96, marking a significant milestone for the company. According to InvestingPro data, the pharmaceutical company, now valued at $1.28 billion, shows signs of being overvalued at current levels, with analysts setting price targets between $6 and $11. Over the past year, the stock has experienced an impressive increase of 175.83%, reflecting strong investor confidence and positive market sentiment. The company’s revenue grew 35.62% over the last twelve months, though it remains unprofitable. This surge in stock price highlights the company’s successful strategies and potential growth prospects in the pharmaceutical sector. The achievement of this 52-week high signals a robust performance, positioning Xeris Pharmaceuticals as a notable player in its industry. Get deeper insights and access to 10+ additional ProTips for XERS with InvestingPro.
In other recent news, Xeris Pharmaceuticals reported earnings for the second quarter of 2025 that exceeded forecasts. The company achieved an earnings per share (EPS) of -0.01, surpassing the expected -0.03, and reported revenue of $71.5 million, which was 11.85% higher than anticipated. In addition to strong earnings results, Xeris Biopharma Holdings announced that the U.S. Patent and Trademark Office issued a new patent for its Cushing’s syndrome treatment, Recorlev. This patent, which covers therapeutic uses that minimize drug-drug interactions, extends protection until March 2040. Furthermore, H.C. Wainwright has assumed coverage on Xeris Pharmaceuticals with a Buy rating and set a price target of $10.00. These developments reflect ongoing interest and potential growth prospects for the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.